Compugen Ltd. Q3 2025 Earnings Recap

CGEN Q3 2025 November 10, 2025

Get alerts when CGEN reports next quarter

Compugen reported strong fundamentals in Q3 2025, driven by its innovation in Fc reduced anti-TIGIT treatments and promising clinical developments aimed at redefining cancer therapy.

Earnings Per Share Beat

$-0.07 vs $-0.09 est.

+22.2% surprise

Revenue Miss

1891000 vs 14295600 est.

-86.8% surprise

Market Reaction

1-Day +3.09%

5-Day +1.23%

30-Day -0.62%

See CGEN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Introduction of COM902, a fully owned Fc reduced anti-TIGIT monoclonal antibody, highlights Compugen's strategic advantage over Fc active competitors in clinical efficacy and safety.
Partnership with AstraZeneca on rilfrogostomy positions Compugen to benefit from a substantial commercial opportunity, with peak year revenue estimates exceeding $5 billion.
COM701, the only Fc reduced anti-PVRIG antibody in clinical development, targets unmet medical needs in platinum-sensitive ovarian cancer, enhancing Compugen's diverse pipeline.
Potential milestone payments of $758 million through the Gilead partnership on the innovative GS0321 program showcase significant financial upside.
Upcoming data readouts from key programs anticipated in 2026 could catalyze investment interest and market recognition for Compugen’s unique therapies.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CGEN on AllInvestView.